Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 9/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 9/20 | 0.54 |
| ▸ | TNKS | O95271 | 5/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31040971 | 0.84 | DDB1 (0.54) | DDB1CRBNTNKSTNKS2 | |
| SCHEMBL31040960 | 0.81 | DDB1 (0.65) | DDB1CRBNTNKSTNKS2MEN1 | |
| SCHEMBL31040968 | 0.79 | DDB1 (0.68) | DDB1CRBNTNKSTNKS2ALDH1A1 | |
| SCHEMBL23139820 | 0.78 | CRBN (0.58) | DDB1CRBNTNKSTNKS2MEN1 | |
| SCHEMBL24777739 | 0.76 | CRBN (0.53) | DDB1CRBNTNKSTNKS2MEN1 | |
| SCHEMBL23121367 | 0.75 | CRBN (0.58) | DDB1CRBNTNKSTNKS2MEN1 | |
| SCHEMBL31040965 | 0.75 | DDB1 (0.48) | DDB1CRBNMEN1ALDH1A1KMT2A | |
| SCHEMBL31040967 | 0.74 | DDB1 (0.65) | DDB1CRBNTNKSTNKS2MEN1 | |
| SCHEMBL31040959 | 0.73 | DDB1 (0.73) | DDB1CRBNTNKSTNKS2PARP1 | |
| SCHEMBL17921312 | 0.73 | CYP4F2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240261416-A1 | SYNTHESIS OF NOVEL CEREBLON E3 LIGASE LIGANDS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261416-A1 | SYNTHESIS OF NOVEL CEREBLON E3 LIGASE LIGANDS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CRBN, CUL1, CUL5 | DDB1 188/4885CRBN 1/4885TNKS 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.